Search
Probenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalProbenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
Categories: Compounds used in a research, industrial, or household setting, Preparations With No Effect on Uric Acid MetabolismSynonyms: 4-(N,N-Dipropylsulfamoyl)benzoesäure, 4-(Di-n-propylsulfamoyl)benzoesäureVanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational[L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082ApprovedTrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. … [L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118]
Synonyms: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001), BONTOXILYSIN-ESodium oxybate
go.drugbank.com/drugs/DB09072ApprovedInvestigationalin May 2023. … [L46302] In some countries, sodium oxybate has been investigated and used in alcohol withdrawal syndrome (AWS) to aid abstinence maintenance in alcohol use disorders.[A251440, A251445]
Infliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalIn clinical trials, multiple infusions of infliximab displayed in a reduction of signs and symptoms of inflammatory diseases and induction of remission in patients who have had an inadequate response to … Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection.
Categories: Complex MixturesProducts: Remsima 120mg solution for injection in pre-filled pen, REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120 MG/ML IN PRE-FILLED PENEthoxzolamide
go.drugbank.com/drugs/DB00311ApprovedWithdrawnEthoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.
Linerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Fosdenopterin
go.drugbank.com/drugs/DB16628ApprovedIn 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … [L43075] In September 2022, the EMA approved the use of fosdenopterin.[L43372,L43433]
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigational[eculizumab] in June 2019 and [inebilizumab] in June 2020). … Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD.
Products: ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML, ENSPRYNG 120 mg/1ml solution for injection in pre-filled syringeFerric maltol
go.drugbank.com/drugs/DB15598ApprovedInvestigationalFerric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate … [A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults.